Bistos gets $2.3M lifeline from top shareholder in listing-defence push
What's the deal? BistosDealroom has a profile for this one. Try Dealroom →, a Korean maker of biosignal medical diagnostic devices, raised 3.5 billion KRW (about $2.3 million) in a post-IPO equity round in June 2026. Its largest shareholder, CU Medical SystemDealroom has a profile for this one. Try Dealroom →, took the entire third-party allocation. The company earmarked 2.5 billion KRW for facilities and roughly 1 billion KRW for operations.
Why now? Bistos shares, above 6,000 won early this year, slid to the 2,000-won range, pushing its market value below the 15 billion KRW minimum for staying listed. From July 2026, that threshold rises to 20 billion KRW, raising the stakes on defending the share price.
What's the endgame? CU Medical System acquired a 33.88% stake in Bistos in January 2026, aiming to build a full-line medical device firm. The plan combines Bistos's class 1 and 2 patient-monitoring technology with CU Medical's class 3 heart defibrillator business.
The shareholder's cash injection followed Bistos signing a 2 billion KRW treasury-stock trust contract to stabilise the price. Days earlier, on July 6 2026, Bistos exercised a call option to repurchase 1 billion KRW of the 4 billion KRW convertible bond it issued in March 2026, planning to cancel it and cut potential dilution.
What could go wrong? The March 2026 bond drew scrutiny: 2 billion KRW was routed into Tway Air perpetual convertible bonds, unrelated to Bistos's core business, with CU Medical System guaranteeing up to 130% of the principal. CU Medical System's own history compounds concern — it issued convertible bonds eight times in 2019, and weak results later left creditors seeking early buybacks.
The signal: Bistos has swapped a debt-raising strategy for a share-price defence, and analysts say it has put out the immediate fire. But financial fixes alone won't hold. "If financial responses keep repeating without business results, the price-defence effect can only be temporary," one securities industry official said, adding that operational synergy and earnings will decide whether market trust returns.
Read more: Edaily
Image credit: Rennett Stowe
